BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 343 filers reported holding BIO-TECHNE CORP in Q3 2018. The put-call ratio across all filers is 1.17 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,560,710 | -60.3% | 228,598 | -52.4% | 0.04% | -14.0% |
| Q2 2023 | $39,240,619 | +24.3% | 480,714 | +13.0% | 0.04% | +22.9% |
| Q1 2023 | $31,571,074 | +11095.4% | 425,544 | +42840.9% | 0.04% | +3400.0% |
| Q3 2022 | $282,000 | -28.8% | 991 | -13.3% | 0.00% | 0.0% |
| Q2 2022 | $396,000 | -50.4% | 1,143 | -37.9% | 0.00% | -50.0% |
| Q1 2022 | $798,000 | -98.8% | 1,842 | -98.6% | 0.00% | -98.6% |
| Q4 2021 | $67,064,000 | +0.6% | 129,633 | -5.8% | 0.14% | -10.3% |
| Q3 2021 | $66,668,000 | +121114.5% | 137,582 | +36588.5% | 0.16% | – |
| Q2 2018 | $55,000 | -3.5% | 375 | 0.0% | 0.00% | – |
| Q1 2018 | $57,000 | +16.3% | 375 | 0.0% | 0.00% | – |
| Q4 2017 | $49,000 | – | 375 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brown Capital Management | 2,119,107 | $256,179,000 | 3.12% |
| STONE RUN CAPITAL, LLC | 42,925 | $5,189,000 | 2.67% |
| 440 INVESTMENT GROUP, LLC | 27,820 | $3,363,000 | 2.56% |
| Summit Creek Advisors LLC | 106,517 | $12,877,000 | 2.54% |
| MAIRS & POWER INC | 1,444,480 | $174,623,000 | 2.10% |
| QUANTUM CAPITAL MANAGEMENT | 57,094 | $6,902,000 | 1.63% |
| Select Equity Group, L.P. | 1,709,914 | $206,711,503,000 | 1.57% |
| FRIESS ASSOCIATES LLC | 144,610 | $17,482,000 | 1.53% |
| Tygh Capital Management, Inc. | 61,813 | $7,473,000 | 1.49% |
| First Light Asset Management, LLC | 38,654 | $4,673,000 | 1.48% |